| Item 7.01 | Regulation FD Disclosure. |
On October 9, 2023, Reneo Pharmaceuticals, Inc. (the “Company”) hosted a Key Opinion Leader (“KOL”) meeting utilizing the slide presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On October 9, 2023, the Company announced last patient last visit in the pivotal STRIDE study of mavodelpar in primary mitochondrial myopathies. Topline data results from the STRIDE study are expected in December 2023. In addition, the Company has enrolled over 85% of eligible patients in the Company’s ongoing STRIDE AHEAD study.
The Company anticipates completing the final steps in the clinical process for the STRIDE study in the coming months. Subsequently, the Company plans to share the results of data analysis with the United States Food and Drug Administration (“FDA”) in the first quarter of 2024. The Company expects that the STRIDE and STRIDE AHEAD studies will form the basis of a New Drug Application (“NDA”) to the FDA which is planned for submission in the first half of 2024 and thereafter to additional regulatory agencies.
Forward-Looking Statements
Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the timing of topline data from the STRIDE study, the timing of the final steps in the clinical process for the STRIDE study and for sharing the results of data analysis with the FDA, the prospects of the STRIDE AHEAD study, and the potential filing and timing of an NDA to the FDA and thereafter to additional regulatory agencies. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will,” “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the Company’s business in general, and the other risks described in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
